Information Provided By: 
Fly News Breaks for July 28, 2017
CELG
Jul 28, 2017 | 08:30 EDT
Stifel analyst Thomas Sharader resumed coverage of Celgene with a $155 price target and a Buy rating. He says that the company's Revlimid for multiple myeloma shows no sign of plateauing, and he thinks that its CAR-T programs "look interesting," while its Acceleron partnership "looks promising."
News For CELG From the Last 2 Days
There are no results for your query CELG
